Repligen Corporation $RGEN Shares Sold by Baird Financial Group Inc.

Key Points

• Baird Financial Group reduced its Repligen stake by 15.8% in the second quarter, selling 27,059 shares and retaining 144,571 shares valued at approximately $19.7 million. Institutional investors and hedge funds collectively own 97.64% of the company.
• Analyst sentiment remains positive, with an overall “Buy” consensus and an average price target of $168.57. Recent firms including Citigroup, JPMorgan, and UBS upgraded or raised their targets, while Weiss Ratings improved its view to “Hold.”
• Repligen reported quarterly EPS of $0.54, exceeding estimates of $0.45, while revenue rose 11.9% year over year to $204.13 million. Shares opened at $165.18, compared with a 52-week range of $100.99 to $188.73.

Baird Financial Group Inc. reduced its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 15.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 144,571 shares of the biotechnology company's stock after selling 27,059 shares during the period. Baird Financial Group Inc. owned about 0.26% of Repligen worth $19,725,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in RGEN. ABS Investment Management LLC purchased a new position in Repligen in the second quarter valued at $191,016,000. Measured Wealth Private Client Group LLC acquired a new position in Repligen in the third quarter valued at approximately $29,000. Los Angeles Capital Management LLC purchased a new position in shares of Repligen in the 4th quarter valued at $36,000. Itau Unibanco Holding S.A. increased its position in shares of Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 104 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Repligen during the second quarter worth about $52,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on RGEN. Weiss Ratings upgraded shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, August 13th. Citigroup upgraded shares of Repligen to a "buy" rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. upped their price objective on Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. UBS Group boosted their target price on Repligen from $195.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday. Finally, HSBC cut their price target on Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $168.57.

Repligen Stock Performance

NASDAQ RGEN opened at $165.18 on Friday. The business has a 50 day moving average price of $158.22 and a 200 day moving average price of $135.29. The company has a market capitalization of $9.32 billion, a P/E ratio of 226.27, a PEG ratio of 3.01 and a beta of 1.05. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the previous year, the firm earned $0.26 EPS. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts expect that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Activity

In other news, CFO Jason Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.